There were 1,828 press releases posted in the last 24 hours and 359,044 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
BeiGene Announces Acceptance of its First New Drug Application for Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma by China Drug Administration

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image